NIH licenses COVID-19 research technologies to WHO initiative

The Biden-Harris administration has announced that the NIH has licensed COVID-19 research technologies and vaccine candidates to the Medicines Patent Pool (MPP).

Working with the WHO’s COVID-19 Technology Access Pool (C-TAP), the NIH will provide licenses to enable manufacturers to use the technologies to develop COVID-19 vaccines, treatments and diagnostics.

In total, NIH is providing 11 COVID-19 technologies under two licenses, bringing the number of technologies licenses to MPP to the following 14 items:

A VSV-EBOV-based vaccine candidate. This SARS-CoV-2 vaccine candidate is based on a modified approved Ebola vaccine known as Ervebo from Merck & Co. ACE2 Dimer construct (Research tool for drug development). This technology is a plasmid encoding human ACE2 dimers, which refers to two conjoined copies of ACE2. ACE2 is a protein involved in COVID-19 infections. NIH notes that the research tool can help isolate antibodies generated against SARS-CoV-2. …
Read more
  • 0